You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Receptors, chimeric antigen

Showing 1 - 25 of 5,490
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Lymphoblastic Leukemia in Remission Trial in Suzhou (CD19 CAR-T cells and CD19 positive feeder T cells)

Recruiting
  • Acute Lymphoblastic Leukemia in Remission
  • CD19 CAR-T cells and CD19 positive feeder T cells
  • Suzhou, Jiangsu, China
  • +2 more
May 18, 2022

Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia Trial run by the NCI (Anti-cluster of differentiation 19

Terminated
Has Results
  • Lymphoma, B-Cell
  • +3 more
  • Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2022

Brain Tumor, Recurrent, Brain Tumor, Refractory Trial in Houston (HER2-specific T cells)

Recruiting
  • Brain Tumor, Recurrent
  • Brain Tumor, Refractory
  • HER2-specific T cells
  • Houston, Texas
  • +1 more
May 3, 2022

Glioblastoma Multiforme Trial in Chapel Hill (CAR.B7-H3T cells infusion)

Recruiting
  • Glioblastoma Multiforme
  • CAR.B7-H3T cells infusion
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 25, 2022

Head Neck Cancer, Relapse, Recurrent Trial in Chapel Hill (Cyclophosphamide, Fludarabine, Cell Therapy)

Not yet recruiting
  • Head and Neck Cancer
  • +3 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Oct 18, 2023

Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

Not yet recruiting
  • Prostate Carcinoma
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • Cyclophosphamide (Non-IMP, Lymphodepletion)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +4 more
Jul 24, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL Trial in Memphis (biological,

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +2 more
  • CD19-CAR(Mem) T-cells
  • +5 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Aug 5, 2022

Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor Trial in Houston ((C7R)-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Diffuse Intrinsic Pontine Glioma
  • +3 more
  • (C7R)-GD2.CART cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Feb 7, 2022

Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Trial in Houston (CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T

Recruiting
  • Non-Hodgkin's Lymphoma
  • +2 more
  • CD19.CAR-CD28Z T Cells - dose escalation 2
  • CD19.CAR-CD28Z T Cells - dose escalation 1
  • Houston, Texas
  • +1 more
Feb 10, 2022

Leukemia, B-Cell Trial in Houston (Autologous TriCAR T-cells and lymphodepletion chemo)

Not yet recruiting
  • Leukemia, B-Cell
  • Autologous TriCAR T-cells and lymphodepletion chemotherapy
  • Houston, Texas
  • +1 more
Nov 3, 2021

CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study

Not yet recruiting
  • Lymphoma
  • Chimeric Antigen Receptor
  • (no location specified)
Oct 24, 2023

Neuroblastoma Trial (GD2 CAR T cells)

Not yet recruiting
  • Neuroblastoma
  • GD2 CAR T cells
  • (no location specified)
Aug 5, 2023

Prostate Cancer Trial in Germany (Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), UniCAR02-T-pPSMA)

Recruiting
  • Prostate Cancer
  • Cyclophosphamide (Non-IMP)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +3 more
Jan 24, 2022

Acute Myeloid Leukemia (AML) Trial in Germany (Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP))

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Cyclophosphamide (Non-IMP)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +5 more
Dec 28, 2021

Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma Trial in Houston (C7R-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Relapsed Neuroblastoma
  • +6 more
  • C7R-GD2.CART cells
  • +2 more
  • Houston, Texas
  • +1 more
Nov 12, 2021

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

Recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Manufactured Anti-BCMA CAR-T cells
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung Trial (LB2102)

Not yet recruiting
  • Small Cell Lung Cancer Extensive Stage
  • Large Cell Neuroendocrine Carcinoma of the Lung
  • LB2102
  • (no location specified)
Jan 10, 2023

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023